Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(17 sites)
France
Department of Neurology, CHU de Bordeaux - GH Pellegrin, Bordeaux
Department of Neurology, CHU of Lille, Hospital Roger Salengro, Lille
Department of Neuro Ophthalmology, CHU of Lyon, Neurology Hospital Pierre Wertheimer, Lyon
Service de Neurologie sclérose en plaques, pathologies de la myéline et neuro-inflammation - Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) - Hôpital Neurologique Pierre Wertheimer - Hospices Civils de Lyon, Lyon
Department of Neurology University hospital Timone, Marseille